Genpact Wins F&A Contract from AstraZeneca
Genpact (NYSE: G – News), a leader in managing business processes, today announced it has signed a five-year contract to provide global Finance & Accounting (F&A) services to AstraZeneca, one of the world’s leading pharmaceutical companies. Under the terms of the contract, skilled Genpact professionals will work in partnership with the company’s finance team to boost the effectiveness of some of AstraZeneca’s finance and accounting processes as part of the company’s corporate initiative to reduce costs. The multi-million dollar contract will deliver services to over 50 countries.
Commenting on the partnership Graham Russell, Head of Global Transactional Finance AstraZeneca, said, “Streamlining our business processes will enable us to improve the effectiveness of AstraZeneca’s finance function in driving, measuring and reporting business performance, while simultaneously reducing the costs of the finance function.”
Genpact’s F&A practice currently supports more than 80 global enterprises, including five pharmaceutical and two life sciences companies. The partnership with AstraZeneca will further expand Genpact’s client base and broaden its experience in the Life Sciences industry. Leveraging best practices developed through more than a decade of experience in F&A services, Genpact’s F&A experts will provide AstraZeneca with support in a range of areas including procure-to-pay, record-to-report and order-to-cash services. AstraZeneca conducted a competitive search before selecting Genpact.
“We are delighted to be chosen by AstraZeneca to streamline their Finance & Accounting operations,” said Pramod Bhasin, Genpact’s President & CEO. “Our granular knowledge of process, deep insights from handling over 3,000 business processes, global best practices and Lean Six Sigma tools will allow us to contribute substantially to improving the effectiveness of AstraZeneca’s F&A operations and I look forward to an enduring and productive relationship,” he added.
